Compare · MYGN vs NTLA
MYGN vs NTLA
Side-by-side comparison of Myriad Genetics Inc. (MYGN) and Intellia Therapeutics Inc. (NTLA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYGN and NTLA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NTLA is the larger of the two at $2.19B, about 5.1x MYGN ($428.8M).
- Over the past year, MYGN is down 6.9% and NTLA is up 69.5% - NTLA leads by 76.4 points.
- MYGN has been more active in the news (17 items in the past 4 weeks vs 12 for NTLA).
- NTLA has more recent analyst coverage (25 ratings vs 23 for MYGN).
- Company
- Myriad Genetics Inc.
- Intellia Therapeutics Inc.
- Price
- $4.54+3.65%
- $15.66+2.96%
- Market cap
- $428.8M
- $2.19B
- 1M return
- +28.25%
- +31.27%
- 1Y return
- -6.87%
- +69.48%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1995
- 2016
- News (4w)
- 17
- 12
- Recent ratings
- 23
- 25
Myriad Genetics Inc.
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Intellia Therapeutics Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest MYGN
- President and CEO Raha Samraat S. was granted 3,542 shares, increasing direct ownership by 0.33% to 1,068,083 units (SEC Form 4)
- Chief Commerical Officer Donnelly Brian J was granted 5,000 shares, increasing direct ownership by 0.88% to 573,363 units (SEC Form 4)
- Director Kumar Rashmi sold $66,843 worth of shares (15,000 units at $4.46) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 171,889 units (SEC Form 4)
- Director Skovronsky Daniel was granted 59,701 shares, increasing direct ownership by 44% to 195,507 units (SEC Form 4)
- Director Newcomer Lee Nisley was granted 59,701 shares, increasing direct ownership by 45% to 191,842 units (SEC Form 4)
- Director Davis Mark Steven was granted 59,701 shares, increasing direct ownership by 127% to 106,665 units (SEC Form 4)
- Director Phanstiel S. Louise was granted 59,701 shares, increasing direct ownership by 21% to 341,652 units (SEC Form 4)
- Director Dreismann Heinrich was granted 59,701 shares, increasing direct ownership by 35% to 231,145 units (SEC Form 4)
- Director Reitan Colleen F was granted 59,701 shares, increasing direct ownership by 65% to 152,030 units (SEC Form 4)
- Director Bisaro Paul was granted 59,701 shares, increasing direct ownership by 61% to 157,142 units (SEC Form 4)
Latest NTLA
- Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
- Director Verwiel Frank was granted 9,200 shares, increasing direct ownership by 35% to 35,148 units (SEC Form 4)
- Director Keresty Georgia was granted 9,200 shares, increasing direct ownership by 29% to 41,083 units (SEC Form 4)
- Director Goodman Jesse was granted 9,200 shares, increasing direct ownership by 38% to 33,559 units (SEC Form 4)
- Director Goff Brian was granted 9,200 shares, increasing direct ownership by 39% to 32,609 units (SEC Form 4)
- Director Cohen Fred E was granted 9,200 shares, increasing direct ownership by 4% to 216,653 units (SEC Form 4)
- Director Chase William J was granted 9,200 shares, increasing direct ownership by 7% to 143,893 units (SEC Form 4)
- Director Bhanji Muna was granted 9,200 shares, increasing direct ownership by 34% to 36,403 units (SEC Form 4)
- Intellia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders